Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | NMT1 | P30419 | 5/20 | 0.37 |
| ▸ | NMT2 | O60551 | 4/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25517030 | 1.00 | GLP1R (0.41) | GLP1RNMT1NMT2CTSLCTSB | |
| SCHEMBL24629759 | 0.98 | GLP1R (0.42) | GLP1RNMT1NMT2FOLH1CAPN1 | |
| SCHEMBL31384219 | 0.92 | GLP1R (0.49) | GLP1RFOLH1CAPN1 | |
| SCHEMBL29326160 | 0.90 | GLP1R (0.46) | GLP1RNMT1NMT2FOLH1CAPN1 | |
| SCHEMBL29727797 | 0.88 | GLP1R (0.47) | GLP1RFOLH1CAPN1 | |
| SCHEMBL30998154 | 0.86 | GLP1R (0.47) | GLP1RNMT1NMT2FOLH1 | |
| SCHEMBL29326632 | 0.86 | GLP1R (0.47) | GLP1RNMT1NMT2FOLH1 | |
| SCHEMBL24630312 | 0.86 | GLP1R (0.47) | GLP1RNMT1NMT2FOLH1 | |
| SCHEMBL29328987 | 0.86 | GLP1R (0.47) | GLP1RFOLH1CAPN1 | |
| SCHEMBL24629772 | 0.85 | GLP1R (0.40) | GLP1RNMT1NMT2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | GLP1R 2531/4885NMT1 3418/4885NMT2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.